Trial Profile

A mass balance study of mesdopetam in healthy volunteers

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mesdopetam (Primary)
Indications Parkinson's disease
Focus Pharmacodynamics
Sponsors Ipsen

Most Recent Events

21 Aug 2023 Status changed from planning to completed, according to a IRLAB Therapeutics media release.
07 Sep 2022 New trial record
06 Sep 2022 According to a IRLAB Therapeutics media release, the Ipsen to conduct three clinical pharmacology studies in healthy volunteers including a pharmacokinetic, a drug-to-drug interaction, and a mass balance study expected to be completed between Q3 2022 and Q1 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com